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ABSTRACT
Helicobacter pylori (Hp) infection is the most common chronic bacterial infection in human. The role of Hp
infection in various GI disorders had been widely accepted. However, further studies have found new
extragastrointestinal involvement such as urticaria. Chronic urticaria is a common disorder that has complex
pathophysiologic mechanism. As mater of fact, etiology remains unclear in most of the cases. This condition is
called Idiopathic Chronic Urticaria. Several studies had shown high prevalence of Hp infection in patients
with ICU and improved symptoms after eradication therapy of Hp. This observation had suggested that Hp has
important role as etiologic factor in some cases of ICU. The presence of Hp infection and its role in ICU should
be proven before initiating eradication therapy, so that irrational used of drugs and antibiotics resistance can
be prevented.
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INTRODUCTION
To date, Helicobacter pylori (Hp) infection is
considered as the most frequent chronic bacterial
infection in human.1 The role of Hp infection as
the etiology of various gastrointestinal diseases had been
widely accepted. Gastrointestinal disorders that frequently
associated with Hp infection are active chronic gastritis,
peptic ulcer, gastric malignancy and gastric mucosa-
associated lymphoid tissue (MALT) lymphoma.1 Further
studies had found Hp involvement in various extra
gastrointestinal disorders.2,3
Chronic urticaria (CU) is a common disorder and
involves complex pathophysiological mechanism.
Infections (bacterial, viral, fungal and protozoa),
psychological factors, neoplasm, and food additives had
been reported as initiating factor. However, it needs
furthers studies to confirm this.1,4 In fact, etiology remains
unclear in most of cases of CU and this condition is called
idiopathic chronic urticaria (ICU).1 Recently, ICU has
become an enigma in dermatology field.
Several studies had shown high prevalence of Hp
infection in patients with ICU and improved symptoms
after eradication therapy of Hp. This observation had
suggested that Hp has important role as the etiology in
some cases of ICU.1 The presence of Hp infection and
its role in ICU must be confirmed before initiating
eradication therapy, so that irrational therapy and
antibiotics resistance can be avoided.
EPIDEMIOLOGY
Helicobacter pylori are gram negative bacteria,
microaerophyllic, spiral shaped, length of 2.5-4.0 µm and
width of 0.5-1.0 µm, and having 4-6 flagella in one of its
tip.2,5-7 It always gives positive result on peroxide,
catalase, and urease test.2 At first, Hp was considered as
one species of genus Campylobacter, but since 1989
Helicobacter was classified into its own genus and
Helicobacter pylori was one of the species.6-8 There
are two phenotypes of Hp: Type 1 which expresses
cytotoxin-associated gene antigen (CagA) and
vacuolating cytotoxin-associated gene antigen (VacA), and
type 2 which does not express gene antigen.2,9  Type 1
bacteria is much more pathogenic and results more
severe inflammatory response than bacteria type 2.2,8 Most
of Hp infection involve bacteria type 1.9
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Helicobacter pylori infection is widely found all over 
the world with various prevalence figures.2,9 Prevalence  
is higher in accordance to higher age and low  
socio-economic condition.2,8,9-11 Prevalence in young adult  
in developing countries was approximately 80% while in  
developed  countries  it  was  only 20-50%.9,10 
In developing countries, Hp infection occurred in younger 
people compare to those in developed countries.2 
Infection in adults is usually chronic condition and non 
responsive to therapy, while in children spontaneous 
resolve is common.9 
 
IDENTIFICATION 
Mode of transmission of infection is through 
fecal-oral route and is more frequent in children.9 
Transmissions may be through body fluid such as vomit 
substance, saliva, feces, drinking water, or food.8-10 Self 
and environment hygiene factor are influenced by 
bacterial transmission.2,9 Transmission from animals has 
never been proven yet.9 
Hp infection can be detected through invasive and non  
invasive examinations (specimen can be obtained from  
endoscopic biopsy procedure) such as culture, histologic  
examination, rapid urease test (CLO test , pronto dry,  
MIU), and polymerase chain reaction (PCR).2,5,12 Non  
invasive examinations include urea breath test (UBT),  
serologic test, Helicobacter pylori stool antigen (HpSA) 
and urine-HpELISA.5,7,13-22 
To date, Urea Breath Test (UBT) examination is  
the most widely used test because it is very simple to  
perform, non invasive and has high reliability with high  
sensitivity of 90-98% and specificity of 92-100%.2,12,16  
UBT may be used to detect active infection and  
diagnose early infection and monitor eradication  
therapy.2,9,14-16 Urine-Hp ELISA introduces new  
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sensitivity of 94.4%, and specificity of 96.9%, simple to 
perform, not expensive and can give fast result.17 
ETIOLOGY 
The role of Helicobacter pylori as etiology of  
gastrointestinal disorder has been widely accepted.  
Gastrointestinal disorders frequently associated with Hp  
infection are active chronic gastritis, peptic ulcer, gastric  
malignancy, and gastric mucosa-associated lymphoid  
tissue lymphoma.1,2,5,6,8-12 Recent studies had found  
relation  between  Hp  infection  and  various  
extragastrointestinal disorders such as cardiovascular  
disease  (arteriosclerosis,  myocardial  infarct, 
Henoch-Schonlein purpura, autoimmune thyroiditis,  
idiopathic arrhythmia, Parkinson’s disease), dermatologic  
disorder (idiopathic chronic urticaria, rosasea, alopesia  
areata, numularis dermatitis) and other diseases like iron  
deficient anemia, growth retardation, extragastric MALT- 
lymphoma, diabetes mellitus, hepatic encephalopathy and  
late menarche.2,23 The Hp bacteria produces some toxins  
(exotoxins) which not only destroy gaster and duodenum  
but also interact with extragastrointestinal tissue.3 
TREATMENT 
The mainstay of eradication therapy of Hp infection  
is total elimination of organism. If the condition is  
obtained, then the possibility of re-infection is rarely  
occurred.9 Eradication regimen should reach cure rate of  
≥ 80%, minimal side effect and low drug induced  
resistance.9 Gastric acid may influence effectiveness of  
some antimicrobial agents and usually is combined with  
proton pump inhibitor (PPI) or ranitidine-bismuth  
citrate.9,24,25 Nowadays, there are 8 regimens of 
eradication therapy which had been recommended by Food 
and Drug Administration (FDA).5,9 
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Table 1. Exotoxins Produced by Helicobacter pylori and Work in Extragastrointestinal Tissue.3 
Factor Produced Source Toxic effect/s 
Ammonia H. pylori urease Inhibition of protein degradation and vacuolation of 
lysosomes 
Lysolecithin H. pylori phospholipases Cytotoxic compound leading to ulceration 
Acetaldehyde H. pylori alcohol 
dehyrogenase 
Denaturation of proteins and induction of lipid 
peroxidation 
Vacuolating cytotoxin 50% of H. pylori organism Vacuolation of eukaryotic cells via unknown 
mechanism 
Haemolysin H. pylori phospholipase ? Haemolysis 
Platelet activating factor Unknown Potent inflammatory mediator in various organs 
Mucolytic factor Unknown Degradation of mucin 





























The potential eradication from these 8 regimens was 
ranged between 61-94%.5 In general, triple therapy  
regimen (2 antibiotics + 1 antisecretory) has better  
eradication potential compare to dual therapy.5 Regimen  
consists of amoxicillin + chlarythromycin + PPI is the first  
line therapy   according to national consensus of  
management of Hp infection (2003).26 Therapy is given  
for 1 week and considered successful if UBT/HpSA or  
histopathologic examination that is conducted 4 weeks post  
therapy is negative.26 
 
IDIOPATHIC CHRONIC URTICARIA 
Idiopathic Chronic Urticaria (ICU) is chronic urticaria  
which etiology cannot be identified after careful  
anamnesis, physical examination and supporting  
examination.27 Physics urticaria and vasculitis urticaria  
are not included in ICU.28 Incidence and prevalence of  
ICU had not been very clear but estimated to be 0.1-3%  
of population.29 Incidence in women was twice than in  
men.27 There was 80-90% cases of chronic urticaria were  
found to be ICU.27,30 Histologically, ICU demonstrated  
non necrotic perivascular lymphocytic infiltrates and mast  
cell accumulation.31,32 Further studies classified ICU into  
two subgroup, ICU presumed to be caused by  
autoimmune disorder (autoimmune chronic urticaria) and  
chronic urticaria with unknown etiology (truly 
idiopathic).27,33 
Data had showed the association between ICU and  
autoimmune thyroiditis and this had encouraged studies  
























revealed autoimmune thyroiditis prevalence in ICU was 
14-20%.34,35 
Study on autoimmune disorder in ICU had identify 
successfully autoantibody to high affinity IgE receptor 
sub unit α (FcεRIα) in 1/3 cases of ICU.28,29,33-42 Hyde et 
al was the first researcher who reported  the presence of 
autoantibody and concluded its role in pathogenesis of 
ICU.38 Autoantibody to  had been proven in vitro could 
stimulate histamine release from mast cell and 
basophil.27,28,38 The role of autoantibody to FcεRIα in 
the pathogenesis of ICU supported by evidence that this 
autoantibody was not found in healthy people. There was 
also clinical improvement of patients with ICU who 
underwent plasmapheresis therapy.38 
Further studies found incidence autoantibody to  
FcεRIα in ICU was higher (35-70%). In fact, this  
autoantibody was also known to be the isotype of IgG  
(IgG1 and IgG3).28,33,41  Autoantibody IgG1 and IgG3 were  
called functional antibody because they could activate  
complements (C5a) and release mediator from mast cell  
and basophil.36,38-44 Actually, this autoantibody is also found  
in other autoimmune diseases such as pemfigus vulgaris  
(39%), dermatomyositis (36%), SLE (20%), and bullous  
pemfigoid (13%).42 However, autoantibody to FcεRIα in  
other autoimmune diseases involves nonfunctional IgG2  
and IgG4 which could not activate complement and  
release mediator from mast cell and basophil.36,42  
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Table 2. Choice of Therapeutic Regimen of Helicobacter pylori Eradication Recommended by FDA.5 
Omeprazole 40 mg QD + Clarithromycin 500 mg TID x 2 weeks, then omeprazole 20 mg QD x 2 weeks; 
or 
Ranitidine bismuth citrate (RBC) 400 mg BID + clarithromycin 500 mg TID x2 weeks, then RBC 400 mg 
BID x 2 weeks 
or 
Bismuth subsalicylate (Pepto Bismol) 525 mg QID + metronidazole 250 mg QID + tetracycline 500 mg 
QID x 2 weeks + H2 receptor antagonist therapy as directed x 4 weeks 
or 
Lansoprazole 30 mg BID + amoxicillin 1 g BID + clarithromycin 500 mg TID x 10 days 
or 
Lansoprazole 30 mg TID + amoxicillin 1 g TID x 2 weeks 
or 
RBC 400 mg BID + clarithromycin 500 mg BID x 2 weeks, then RBC 400 mg BID x 2 weeks 
or 
Omeprazole 20 mg BID + clarithromycin 500 mg BID + amoxicillin 1 g BID x 10 days 
or 
Lansoprazole 30 mg BID + clarithromycin 500 mg BID = amoxicillin 1 g BID x 10 days 
 Although not FDA approved, amoxicillin has been substituted for tetracycline for patients for whom tetracycline is not 
recommended 
 This dual therapy regimen has restrictive labeling. It is indicated for patient who are either allergic or intolerant to 
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In small part of ICU cases (10%), it was also found 
the autoantibody to IgE molecule.27,37,39 The role of this 
autoantibody is still unknown. Autoantibody binding to IgE 
molecule on the surface of mast cell or basophil was 
presumed to stimulate the release of mediators.27,37,39  
 Tong et al, concluded that in autoimmune chronic  
urticaria (ACU) there were 3 groups of patients. First 
was those who poses autoantibody to FcεRIα, second 
who poses autoantibody to IgE and third those who poses 
circulating factors that could stimulate mediator release 
from mast cell and basophil.39 Study on circulating 
factors has been conducted until now.39 
Bakos et al, found antibody IgG and IgA to 
Hp-lipoprotein 20 in patients with chronic urticaria and 
Hp infection. The autoantibody was presumed to have 
role in the pathogenesis of chronic urticaria.45 
Patients with ACU usually have more urticaria  
lesions, more wide, severe itch and more systemic  
symptoms than patients with ICU but no autoantibody.28  
Other autoimmune diseases are also commonly found in  
ACU.28 Recently, there were found HLA-DR4, DQB  
0302 (DQ8), DQA0302 and DQA0301 in patients with  
ACU.29,37,46 Diagnosis of ACU was based on detection  
of autoantibody by serum autologue skin test, histamine  
release assay (HRA), ELISA, or immunoblotting  
analysis (western blot analysis).28,29,33,47,48 Patients with  
ACU were more resistant to therapy and had more  
progressive disease course compare to nonautoimmune  
urticaria.33 Immunosuppressive therapy such as  
cyclosporine is recommended to severe form of ACU.33,47  
Other therapy had been studied including intravenous  
immunoglobulin, plasmapheresis and the use of  
























Volume 6, Number 2, August  2005 
About 40-60% cases of ICU had no etiology (truly 
idiopathic) and no autoantibody was found in the sera.27,33 
Infection and food additives were suspected to be 
the causal factors. However, it would need further 
studies to confirm this.27 Diagnosis of true ICU had to be 
considered in patients with persistent ICU who is non 
responsive to therapy and no antibody found on 
laboratory examination.33 
ASSOCIATION OF HELICOBACTER PYLORI AND 
IDIOPATHIC CHRONIC URTICARIA 
Many studies had shown high prevalence of Hp  
infection in patients with ICU along with remission of sign  
and symptoms after eradication therapy of Hp. Early  
reports had demonstrated prevalence of Hp infection in  
55-80% cases and clinical remission in 95-100% of  
patients who were given eradication therapy.1,20,50,51 This  
finding had suggested the role of Hp as the etiologic  
factor in some cases of ICU.1 Further studies had found  
various prevalence and frequency of association.2,20,50,52  
 There had been speculations and theory about  
mechanism involving Hp infection in chronic urticaria. One  
of the theory stated that chronic infection could stimulate  
immunologic system by release of mediators and hence,  
cause nonspecific increased sensitivity of vascular wall  
to certain substances which can increase vascular  
permeability.2 There were also increased production of  
interleukin-8 (IL-8), platelet activating factor (PAF), and  
leucotrien B4 and C4 in gastric mucosa of patients  
infected by Hp. Those mediators had widely known role  
in skin metabolism.2 
Liutu et al, Andersen et al, Aceti et al had found  
specific IgE antibody to Hp in patients with chronic  
urticaria.*  Figura et al had failed to detect the antibody 
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Table 3. Percentage of Helicobacter pylori Infection in Patients with Chronic 
Urticaria.2 
Authors and Years Number of Cases 
Percentage  
H. pylori (%) Country 
Wustlich et al, 1999 
Valsecchi and Pigatto, 1998 
Liuty et al, 1998 
Schnyder et al, 1999 
Di Campli et al, 1998 
Kalas et al, 1996 
Ozkaya-Bayazit et al, 1998 
Kolibasova et al, 1994 
Wedi et al, 1998 
Tebbe et al, 1996 
Bonamigo et al, 1999 
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by Western blot technique.* However, all studies 
mentioned above had also showed increased release of  
histamine in patients with ICU and Hp infection.*  
 Hizal et al, concluded that Hp infection might  
stimulate production of IgE antibody because of cross  
reaction between Hp antigen and gastric parietal cell.53  
Other possibilities are Hp infection has caused  
inflammation in gastrointestinal tract and ease  
the absorption of antigen or unmasking antigen that had  
been presented before.53 Once this occurred, the IgE  
antibody will be produced continuously and urticaria may  
not be resolved eventhough eradication therapy is given.53  
 The effect of eosinophyl in Hp infection had not much  
been studied yet. Bacterial infection may stimulate  
infiltration and degranulation of eosinophil. It is presumed  
that toxic protein produced by eosinophil has role in  
inflammation process.2Bakos et al, analyzed the relation  
between Hp infection in ICU with or without autoimmune  
thyroiditis.34 Previous reports had shown prevalence of  
autoimmune thyroiditis in 14-20% cases of ICU.34,35 Bakos  
et al had demonstrated that Hp (CagA plus strain) had 
important role as stimulating factor in ICU with 
autoimmune thyroiditis. Monoclonal antibody to Hp CagA  
plus strain had reacted positively with thyroid follicular  
cell. There is similar molecular structure between  
peroxide enzyme of human thyroid and peroxide enzyme  
of Hp so that immunologic cross reaction may occur.34  
 New study by Atta et al, had tried to detect auto  
antibody to thyroid, autoantibody IgE and autoantibody to  
C1 INH in patient with and without Hp infection.54  
Studies demonstrated titer of autoantibody to thyroid was  
low in both group and there was no significant  
difference of level of IgE antibody in both groups.  There  
was increased circulating immune complex from  
autoantibody C1 INH in patients with CU and Hp  
infection. The role of immune complex remains unclear,  
but it was presumed it was produced caused by  
phagocytosis disorder during Hp infection. In general, Atta  
et al concluded that there was no association  
between Hp infection and autoantibody production in  
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TOTAL 266    59/191 7/38 11/45 10/74 
A: amoxicillin, B: bismuth subsalicylate, C: clarithromycin, L: lansoprazole, M: metronidazole, O: omeprazole, T: tetracycline 
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Eradication therapy in ICU with Hp infection
Many studies had been conducted to evaluate
effectiveness of eradication therapy in ICU with Hp
infection. The results were varied and might be caused
by different diagnostic methods, therapeutic regimen, and
period of post therapy observation.1
From table 4 above, it showed that remission rate was
30.9% in patients with urticaria and Hp infection who were
given eradication therapy, 21.7% in group of patients who
did not get eradication therapy and 13.5% in control group
who had no Hp infection. Low successful rate was
probably caused by antibiotics resistance and many
studies used serologic test as eradication therapy
effectiveness parameter.1,53 Serologic test could not
indicate active Hp infection. On the other hand,
eradication therapy can only result in resolution of
urticaria in patients with active Hp infection. Clinicians
should monitor therapeutic effectiveness using Urea
Breath Test (UBT).1
CONCLUSION
 ICU is still an enigma in dermatology field. Several
studies had shown high prevalence of Hp infection in
patients with ICU and improved symptoms after
eradication treatment of Hp. Some experts had
recommended Hp infection screening test in management
of ICU. However, it needs further studies to confirm Hp
as the etiology of ICU. Remission of urticaria after
eradication therapy of Hp could not ascertain causal
relationship because combination of antimicrobial agents
used in eradication treatment of Hp might also eradicate
other source of infection that induced urticaria.
To prevent irrational therapy, adverse effects of drugs,
and the risk of antibiotics resistance, it is recommended
that eradication therapy is indicated only in patients with
ICU and has been proven to have Hp infection.
Effectiveness of eradication therapy should be monitored
using Urea Breath Test (UBT).
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